vimarsana.com
Home
Live Updates
FDA Grants Fast Track Designation to Tamibarotene/Azacitidine/Venetoclax for RARA-Overexpressed AML : vimarsana.com
FDA Grants Fast Track Designation to Tamibarotene/Azacitidine/Venetoclax for RARA-Overexpressed AML
Tamibarotene plus azacitidine and venetoclax has received FDA fast track designation for newly diagnosed, unfit, RARA-overexpressed AML.
Related Keywords
Davida Roth ,
,
Syros Pharmaceuticals ,
Fda ,
Aml ,
Relapsed Or Refractory Acute Myeloid Leukemia ,
Nct04588922 ,
Arara ,
Fast Track Designation ,
vimarsana.com © 2020. All Rights Reserved.